As a provider of induced pluripotent stem cell (iPSC) products and technologies, you need to make effective product development decisions, generate improved revenues, and take market share from your competition.
To do this, you need to be educated about prevailing market conditions. This involves knowing which stem cell types are showing the most promise and understanding methods through which these cells could be commercialized.
Stem cells are still a relatively new discovery, as the first stem cells were discovered in human cord blood in 1978, the first mouse embryonic stem cells were derived in 1981, and it was not until 2006 that induced pluripotent stem cells (iPSCs) were produced for the first time.
The Market for Induced Pluripotent Stem Cell (iPSC) Products
Since the discovery of iPSCs, a large and thriving research product market has grown into existence, largely because the cells are completely non-controversial and can be generated directly from adult cells. Today, the number of iPSC products sold worldwide is growing at an annual rate of 14.7%. In addition, 22% of all stem cell researchers now self-report having used iPSCs within a research project.
It is clear that iPSCs represent a lucrative product market, but methods for commercializing this cell type are still being explored, as clinical studies investigating iPSCs continue to increase in number.
At this time, nearly all clinical studies involving iPSCs are for the creation and evaluation of iPSC lines from specific patient populations, in order to determine if these cell lines could be a good model for a disease of interest in that patient population. (See ClinicalTrials.gov for a current list of these trials.)
However, the first clinical study involving transplant of iPSCs into humans began in August 2013 to investigate the use of iPSCs in treating patients with macular degeneration. This clinical study is now underway at the Riken Center in Japan, led by Masayo Takahashi.
In addition, a new patent challenge has exploded on the stem cell scene. The famous “Yamanaka Patent” (U.S. Patent No. 8,058,065) for cellular reprogramming of iPSCs is now being challenged in a patent lawsuit by a group called “BioGatekeeper.” If successful in canceling the Yamanaka Patent, this could create incredible innovation in the stem cell/regenerative medicine sector.
Induced Pluripotent Stem Cell (iPSC) Infographic
Due to these exciting and rapidly changing market conditions, this infographic below explores the business of commercializing iPSC products and technologies.
It specifically considers trends in the:
- Production of iPSC research products
- Funding of iPSC clinical research studies
- Major advances in cellular therapy and biobanking involving iPSCs
To learn more about the iPSC sector and further your competitive advantage within the marketplace, view the full infographic below.
Future Posts about the Stem Cell Industry
To receive future posts about the stem cell industry, sign-up here. We will never share your information with anyone, and you can opt-out at any time.
About Us
BioInformant is the only research firm that has served the stem cell sector since it emerged. Our management team comes from a BioInformatics background – the science of collecting and analyzing complex genetic codes – and applies these techniques to the field of market research. BioInformant has been cited by promient news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking.
To learn more about the iPSC industry, view the “Complete 2015-16 Induced Pluripotent Stem Cell Industry Report” now.
